Altris AI

Altris AI is a pioneering web platform utilizing artificial intelligence to automate the analysis of Optical Coherence Tomography (OCT) scans. This innovative system excels in detecting over 70 retina pathologies, including rare conditions, and effectively discerns between pathological and non-pathological b-scans. By significantly expediting the OCT examination process, Altris AI not only enhances diagnostic accuracy but also elevates the overall efficiency of this critical medical procedure. This groundbreaking solution holds notable significance in the biotechnology, education, healthcare, and mobile industries. Founded in 2017 and headquartered in the United States, Altris AI has garnered substantial support, most recently securing a $1.00M Venture Round investment on 14 December 2022. The investors involved in this milestone include Artesian, Brinc, Runa Capital, JOINT JOURNEY, Chicago Booth Angels, The University of Chicago Booth School of Business, and Farmak. Furthermore, Altris AI is firmly anchored in compliance, boasting full GDPR compliance and robust data encryption to prevent unauthorized access. With a CE certificate already in place and FDA clearance underway, the company's commitment to stringent regulatory standards is evident. Presently utilized in over 30 eye clinics and optometry centers worldwide, Altris AI's impact on the field of ophthalmology is poised for substantial growth and recognition.